
Antibody–drug conjugates (ADCs) have established roles in the treatment of several hematologic malignancies, although clinical outcomes vary substantially across constructs and treatment settings. Target biology influences ADC delivery, while intracellular trafficking, linker processing, and the properties of released species shape intracellular drug exposure, bystander activity, and cellular injury. This Review integrates these mechanisms with clinical evidence stratified using a descriptive Levels of Evidence (LoE I–V) framework, while identifying preclinical or translational findings and abstract-only reporting separately. Same-target ADC comparisons can inform linker–payload redesign, although existing clinical evidence rarely isolates the contribution of individual design features. We also examine resistance across the ADC therapeutic cascade, mechanistically distinct sources of toxicity, and integration with chimeric antigen receptor (CAR) T-cell therapy and T-cell engagers. Candidate biomarkers encompass target expression and heterogeneity, intracellular processing and catabolite transport, drug efflux, and payload sensitivity, with differing levels of clinical support. Linker–payload pharmacology complements target-based classification but is insufficient on its own to guide ADC selection or treatment sequencing. Prospective target-anchored studies incorporating pharmacokinetic and biomarker assessments are needed to determine whether specific ADC design modifications improve the clinical benefit–risk balance and whether candidate biomarkers can guide patient selection.
CD8⁺ T cells are central cytotoxic effectors of anti-tumor immunity, but tumor-infiltrating CD8⁺ populations are functionally heterogeneous and include tumor-reactive, dysfunctional, and bystander states. Although the past decade of cancer immunology has focused largely on how local interactions within the tumor microenvironment shape these states, clinical observations linking chronic stress, sleep disruption, endocrine comorbidity, and circadian timing to immune checkpoint inhibitor (ICI) outcomes indicate that CD8⁺ T cell function is also modulated far beyond the tumor itself. In this review we adopt a whole-organism perspective to examine how autonomic and sensory neural circuits and the endocrine system act across anatomical compartments to govern CD8⁺ T cell priming, trafficking, metabolism, and exhaustion. We first analyze sympathetic, parasympathetic, and sensory neural axes as systemic effectors mediated by catecholamines, acetylcholine, neuropeptides, and brainstem-driven tone. We then examine endocrine regulation through the hypothalamic-pituitary-adrenal axis, metabolic hormones, and gonadal steroids. We integrate these axes within the tumor microenvironment, where nerve-derived signals, paracrine neuropeptides, and locally amplified glucocorticoid activity form a convergent suppressive network, and at the organismal level through stress amplification loops, sex dimorphism, gut-relayed microbial signaling, and circadian timing. Collectively, this evidence identifies neuro-endocrine signaling as an actionable, mechanistically stratified layer of systemic immune regulation and supports its evaluation as a source of biomarkers and pharmacological targets for sensitizing tumors to ICI therapy. This framework offered here is intended to bridge cancer neuroscience, endocrine oncology, and immunotherapy, and to define the criteria by which the next generation of systems-level immune sensitizers should be evaluated.
Anaplastic large cell lymphoma (ALCL) comprises biologically distinct entities based on anaplastic lymphoma kinase (ALK) expression, itself a reflection of ALK rearrangement status. Even as genetic alterations have been used to subtype ALCL, the outcomes remain heterogeneous, indicating that current genetic subgrouping does not fully stratify risk ALK-negative ALCL. 149 ALCL biopsy samples (ALK-positive, n = 75; ALK-negative, n = 74) with accompanying clinical data were accrued to identify genomic factors that impact on outcomes. Genetic variants, copy number variants and gene expression profiles were assessed. ALK‑negative patients showed inferior overall survival (OS) compared with ALK-positive patients (p < 0.05). ALK‑negative ALCL that harbored TP53 mutations had the poorest overall and progression-free survival compared to ALK-positive or ALK-negative TP53‑wild type cases (p < 0.05). Mutational burden and copy number variation burden were highest in ALK‑negative, TP53-mutated cases compared with either of the other groups (p < 0.05). Finally, we identified a three-gene mutation signature comprised of TP53, KMT2D and TET2 that significantly stratified overall survival risk across the subtypes. Our findings define the differing genomic landscapes underlying ALK-positive and ALK-negative ALCL and point to potential new approaches for risk assessment and targeted therapy strategies.
Reliable biomarkers for cancer early detection, prognostic stratification, recurrence surveillance, and treatment-response prediction remain clinically insufficient. tRNA-derived small RNAs (tsRNAs) are abundant, structurally compact, and recurrently dysregulated in malignancy, and have been widely proposed as liquid-biopsy analytes. Their biogenesis, mechanisms, and therapeutic prospects have been reviewed extensively. What has not been assessed is whether the reported clinical evidence supports the claims attached to it, and that is the question this review addresses. We appraise published circulating tsRNA studies against four criteria that govern progression toward clinical use: analytical validity, cohort design and comparator choice, independent validation, and demonstrated incremental clinical utility. Biology is summarized only where it bears on measurement—the distinct enzymatic routes that generate tRNA-derived fragments and tRNA halves, the terminal chemistries they impose, the modifications that bias library construction, and the extracellular biology that determines what is actually quantified in blood. Candidates are then re-classified by intended use and graded by validation level in a structured evidence table reporting cohort size, comparator group, platform, normalization, diagnostic performance, and validation status. Most candidates rest on single-center retrospective case–control comparisons against healthy donors. Detection in stage I disease has been conflated with early detection, and postoperative decline with rcrrence monitoring. Disease specificity is frequently untested, notably for glycine-GCC-derived fragments, which also rise in active inflammatory bowel disease. No circulating tsRNA has yet demonstrated incremental clinical value in a prospectively validated setting. tsRNAs remain a biologically compelling and analytically tractable biomarker reservoir. Realizing that potential will require standardized pre-analytics, clinically relevant comparators, transfer to analytically validated targeted assays, and independent multicenter validation. We provide a minimum reporting checklist and a nomenclature cross-walk to support this
T-cell engagers (TCEs) are bispecific or multispecific immunotherapeutic molecules that specifically bridge and activate T cells to mediate tumor cell killing. Although TCEs have achieved remarkable clinical success in hematological malignancies, their efficacy in solid tumors remains limited by physical tumor barriers, an immunosuppressive tumor microenvironment, antigen heterogeneity, and off-tumor toxicity. This review systematically summarizes recent engineering strategies for TCEs in solid tumors, including miniaturization and novel expression and delivery technologies to enhance tumor penetration, affinity optimization, integration of costimulatory signals and immune checkpoint blockade, and tumor microenvironment-responsive prodrug designs to balance antitumor immune activity with treatment safety, as well as novel molecular architectures to overcome tumor antigen escape and heterogeneity. We further discuss biomarker-guided patient selection and engineering strategy selection, together with developability and chemistry, manufacturing, and controls (CMC) considerations for clinical translation, and highlight future directions toward precise activation, multimodal synergy, and efficient local enrichment, providing a framework for rational development of TCE-based immunotherapy for solid tumors.